Guardant Health Inc. (NASDAQ: GH) saw its stock price surge 5.14% in pre-market trading on Friday, following the release of its better-than-expected first-quarter 2025 financial results and a positive analyst update.
The cancer diagnostics company reported revenue of $203.5 million for Q1 2025, up 21% from the same period last year and exceeding analyst estimates by 7.1%. The company's net loss narrowed to $95.2 million, with a loss per share of $0.77, which was 7.6% better than expected. These strong results demonstrate Guardant Health's continued growth and improving financial performance in the competitive healthcare sector.
Adding to the positive sentiment, Morgan Stanley raised its price target on Guardant Health to $60 from $52, maintaining an Overweight rating on the stock. This upgrade reflects growing confidence in the company's future prospects. Investors appear optimistic about Guardant Health's outlook, with revenue forecast to grow 17% per annum on average over the next three years, outpacing the 7.0% growth forecast for the US Healthcare industry.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。